文献速递乳腺外科围术期管理与 ERAS

妊娠期乳腺癌诊治的回顾性分析

[Retrospective analysis of diagnosis and treatment of breast cancer in pregnancy].
PubMed 文献 · Zhonghua Wai Ke Za Zhi · 2018-01-01

该研究回顾性分析复旦大学附属妇产科医院2012年1月至2017年7月收治的17例妊娠期乳腺癌患者,中位年龄32岁。13例于妊娠期接受手术,7例接受化疗,15例剖宫产终止妊娠,分娩孕周(36.9±1.3)周。结论认为妊娠期乳腺癌可有效治疗,妊娠期化疗对母胎安全,新生儿结局与孕周有关,应尽可能避免早产。

要点

  • 妊娠期乳腺癌需多学科合作评估母胎风险与收益。
  • 妊娠期化疗对母胎安全,但需大样本长期随访。
  • 新生儿结局与孕周相关,治疗期间应避免早产。

核心结论

  • 妊娠期乳腺癌可进行有效治疗,需多学科合作详细评估母胎个体化风险和收益。
  • 妊娠期化疗对母胎安全,但尚需大样本临床研究和长期随访。
  • 新生儿结局与孕周有关,治疗期间尽可能避免早产。

研究设计与样本

  • 回顾性分析2012年1月至2017年7月复旦大学附属妇产科医院收治的17例妊娠期乳腺癌患者病例资料。
  • 患者年龄25~45岁,中位年龄32岁。
  • 病理分期:0期2例,Ⅱa期1例,Ⅱb期7例,Ⅲa期1例,Ⅲc期2例,Ⅳ期4例。

主要发现

  • 13例于妊娠期接受手术,手术时孕周为(27.7±4.6)周;2例原位癌行单纯乳房切除术,11例行乳腺癌改良根治术。
  • 先期手术的4例未用预防措施,其中2例术后24小时内出现频繁宫缩;后续9例口服硝苯地平预防宫缩,术后未发生明显宫缩。
  • 7例于妊娠期接受化疗,4例三阴型乳腺癌方案为紫杉醇周疗序贯表柔比星+环磷酰胺,另外3例为多西他赛序贯表柔比星+环磷酰胺。
  • 15例剖宫产终止妊娠,2例自然分娩,分娩孕周为(36.9±1.3)周;<35周终止妊娠1例,胎儿因新生儿呼吸窘迫综合征转新生儿ICU且有先天性听力障碍,其余16例存活婴儿预后良好。
  • 中位随访10个月(范围4~27个月),0~Ⅲc期13例中1例术后12个月确诊骨转移,无进展生存率12/13,总体生存率13/13;Ⅳ期4例中1例产后7个月死亡,1例产后8个月出现肝脏新发转移灶,其余2例病情稳定。

临床怎么用

  • 一旦怀疑妊娠期乳腺癌,应积极通过多学科合作详细评估母胎个体化风险和收益。
  • 妊娠期化疗对母胎安全,但需大样本临床研究和长期随访。
  • 治疗期间尽可能避免早产,以改善新生儿结局。

局限性

  • 回顾性分析,样本量17例。
  • 中位随访时间10个月(范围4~27个月),随访时间较短。
  • 妊娠期化疗对母胎的安全性尚需大样本临床研究和长期随访。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the principles of diagnosis and treatment of breast cancer during pregnancy. Methods: Clinical data of patients with breast cancer during pregnancy admitted to Obstetrics and Gynecology Hospital of Fudan University between January 2012 to July 2017 were analyzed retrospectively. A total of 17 patients were diagnosed with breast cancer in pregnancy, the median age was 32 years (range from 25 to 45 years old), pathological staging revealed 2 patient with stage 0, 1 with stage Ⅱa, 7 with stage Ⅱb, 1 with stage Ⅲa, 2 with stage Ⅲc, 4 with stage Ⅳ. Results: Thirteen patients received surgical treatment in pregnancy, the gestational age at surgery was (27.7±4.6) weeks; 2 patients with ductal carcinoma in situ received mastectomy, 11 patients with breast cancer underwent modified radical mastectomy. In patients undergoing surgery during pregnancy, no prophylactic contractions were used in 4 patients who had been treated earlier, there were 2 patients with frequent contractions within 24 hours after operation in these patients. Follow-up 9 patients were given oral nifedipine to prevent contractions, no obvious contractions occurred after the operation. Seven patients received chemotherapy during pregnancy; the chemotherapy of 4 cases of triple negative breast cancer was weekly paclitaxel sequential epirubicin and cyclophosphamide, the chemotherapy of the other three patients was docetaxel sequential epirubicin and cyclophosphamide. Fifteen patients underwent cesarean section to terminate pregnancy, 2 patients underwent spontaneous labor. The gestational age of birth was (36.9 ±1.3) weeks. Less than 35 weeks of termination of pregnancy occurred in one patient, the fetus was delivered to the neonatal intensive care unit due to neonatal respiratory distress syndrome, and suffered from congenital dysaudia. The prognosis of the other 16 survived infants was good. The median follow-up time was 10 months (range from 4 to 27) months, in 13 patients of stage 0 to Ⅲc, one patient were diagnosed with bone metastasis at 12 months after surgery, the remaining 12 patients had no disease progression, the progression free survival rate was 12/13, the overall survival rate was 13/13. Among the 4 patients with stage Ⅳ, one died in 7 months after delivery, one had new liver metastasis in 8 months after delivery. The remaining 2 patients were in stable condition. Conclusions: Breast cancer in pregnancy can be treated effectively, multidisciplinary cooperation and detailed assessment of maternal-fetal risks and benefits are necessary. Chemotherapy during pregnancy is safe for maternal-fetal, but it needed a large sample of clinical studies and long-term follow-up. The neonatal outcome was associated with gestational age, and therefore premature delivery was avoided as much as possible during treatment. 目的:探讨妊娠期乳腺癌的诊治经验。 方法:回顾性分析2012年1月至2017年7月复旦大学附属妇产科医院收治的17例妊娠期乳腺癌患者的病例资料。患者年龄25~45岁,中位年龄32岁。0期原位癌2例,Ⅱa期1例,Ⅱb期7例,Ⅲa期1例,Ⅲc期2例,Ⅳ期4例。 结果: 13例患者于妊娠期接受乳腺癌根治手术,手术时孕周为(27.7±4.6)周,其中2例原位癌行单纯乳房切除术,其余11例行乳腺癌改良根治术;先期接受手术治疗的4例患者未使用任何预防措施,2例患者术后24 h内出现频繁宫缩,后续9例患者予以口服硝苯地平预防宫缩,术后未发生明显宫缩。7例患者于妊娠期接受化疗,其中4例三阴型乳腺癌的化疗方案为紫杉醇周疗序贯表柔比星+环磷酰胺,另外3例患者为多西他赛序贯表柔比星+环磷酰胺。15例患者剖宫产终止妊娠,2例自然分娩,分娩孕周为(36.9±1.3)周。其中<35周终止妊娠1例,胎儿娩出后因"新生儿呼吸窘迫综合征"转新生儿ICU,且有先天性听力障碍;其余新生儿体重、身高、智力发育等均良好。17例患者接受4~27个月的随访,中位随访时间为10个月。0~Ⅲc期13例患者中1例术后12个月确诊骨转移,其余12例患者病情无进展,无进展生存率为12/13,总体生存率为13/13。Ⅳ期4例患者中,1例在产后7个月死亡,1例在产后8个月出现肝脏新发转移灶,其余2例患者目前病情稳定。 结论:妊娠期乳腺癌可以进行有效治疗,一旦怀疑妊娠期乳腺癌,应积极通过多学科合作详细评估母胎个体化风险和收益。妊娠期化疗对于母胎是安全的,但尚需大样本临床研究和长期随访。新生儿结局与孕周有关,在治疗期间尽可能避免早产。.

来源:Zhonghua Wai Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang FW, Fu SM, Jin YC, et al. [Retrospective analysis of diagnosis and treatment of breast cancer in pregnancy]. Zhonghua Wai Ke Za Zhi. 2018. PMID: 29397624. doi:10.3760/cma.j.issn.0529-5815.2018.02.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。